Latest News in the pharma Industry

Research & Development

Experimental dengue vaccine protects all recipients in virus challenge study

Experimental dengue vaccine protects all recipients in virus challenge study

17 Mar 2016

Vaccine developed by NIH and FDA scientists.

Read more 
Monoclonal antibodies headline innovation in gastric cancer treatment pipeline

Monoclonal antibodies headline innovation in gastric cancer treatment pipeline

17 Mar 2016

GBI Research says pipeline consists of 29% monoclonal antibodies.

Read more 
FDA grants Genentech’s cancer immunotherapy atezolizumab Priority Review for advanced bladder cancer

FDA grants Genentech’s cancer immunotherapy atezolizumab Priority Review for advanced bladder cancer

15 Mar 2016

FDA will make a decision on approval by 12 September 2016.

Read more 
FDA approves Xalkori for the treatment of patients with ROS1-positive metastatic NSCLC

FDA approves Xalkori for the treatment of patients with ROS1-positive metastatic NSCLC

13 Mar 2016

Xalkori is the first and only FDA-approved biomarker-driven therapy for ROS1-positive metastatic NSCLC.

Read more 
PhoreMost and The Wistar Institute collaborate to identify new druggable targets in cancer, immunotherapy and ageing

PhoreMost and The Wistar Institute collaborate to identify new druggable targets in cancer, immunotherapy and ageing

10 Mar 2016

Collaboration will use Siteseeker — a new ‘phenotypic’ screening platform that exploits the dynamics of a live-cell environment to uncover hidden druggable target sites across the entire human genome — to find new therapeutic options.

Read more 
EMA launches PRIME — paving the way for promising medicines for patients

EMA launches PRIME — paving the way for promising medicines for patients

8 Mar 2016

New scheme supports European Commission priorities.

Read more 
New understanding of the mechanism of neurodegeneration leads to a novel approach to treatment for Alzheimer’s disease

New understanding of the mechanism of neurodegeneration leads to a novel approach to treatment for Alzheimer’s disease

7 Mar 2016

Innovative drug prototype shown to block damaging activity in human cell lines suggests a promising strategy for future therapeutics.

Read more 
FDA accepts sBLA for Keytruda (pembrolizumab) in advanced NSCLC

FDA accepts sBLA for Keytruda (pembrolizumab) in advanced NSCLC

7 Mar 2016

Application based on data from KEYNOTE-010, which showed superior overall survival for patients taking Keytruda compared to chemotherapy in patients with PD-L1 expression on one percent or more of the cancer cells.

Read more 
Adding Spiriva Respimat effective for uncontrolled asthma, regardless of allergy subtype

Adding Spiriva Respimat effective for uncontrolled asthma, regardless of allergy subtype

7 Mar 2016

Spiriva Respimat shown effective in the broad range of asthma patients studied who continued to experience symptoms despite taking other asthma maintenance therapies.

Read more 
Imbruvica (ibrutinib) approved by FDA for the first-line treatment of chronic lymphocytic leukemia

Imbruvica (ibrutinib) approved by FDA for the first-line treatment of chronic lymphocytic leukemia

7 Mar 2016

First FDA-approved chemotherapy-free treatment option for first-line CLL patients.

Read more 
DSMB recommends Celldex's Phase III study of Rintega (rindopepimut) in newly diagnosed glioblastoma be discontinued

DSMB recommends Celldex's Phase III study of Rintega (rindopepimut) in newly diagnosed glioblastoma be discontinued

7 Mar 2016

Study unlikely to meet primary overall survival endpoint in patients with minimal residual disease.

Read more 
Victoza significantly reduces the risk of major adverse cardiovascular events in the LEADER trial

Victoza significantly reduces the risk of major adverse cardiovascular events in the LEADER trial

6 Mar 2016

The safety profile of Victoza in LEADER was generally consistent with previous liraglutide clinical studies.

Read more